DE385517T1 - Arzneimittel zur behandlung von erbrechen. - Google Patents

Arzneimittel zur behandlung von erbrechen.

Info

Publication number
DE385517T1
DE385517T1 DE199090107640T DE90107640T DE385517T1 DE 385517 T1 DE385517 T1 DE 385517T1 DE 199090107640 T DE199090107640 T DE 199090107640T DE 90107640 T DE90107640 T DE 90107640T DE 385517 T1 DE385517 T1 DE 385517T1
Authority
DE
Germany
Prior art keywords
use according
methyl
cytotoxic agent
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE199090107640T
Other languages
English (en)
Inventor
Beecham Pharmaceuticals Gareth John Harlow Essex Cm19 5Ad Sanger
Beecham Pharmaceuticals Gordon Wootton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858506642A external-priority patent/GB8506642D0/en
Priority claimed from GB858509039A external-priority patent/GB8509039D0/en
Priority claimed from GB858531614A external-priority patent/GB8531614D0/en
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of DE385517T1 publication Critical patent/DE385517T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (11)

EP 90107640.6 Beecham Group pic Patentansprüche
1. Die Verwendung einer Verbindung der Formel(II) oder eines pharmazeutisch verträglichen Salzes davon:
(II)
in welcher Rio Wasserstoff, Ci-io-Alkyl, C3-7-Cycloalkyl, C3-6-Alkenyl, Phenyl oder Phenyl-Ci-3-alkyl ist ; und eine der Gruppen, dargestellt durch Rll,Ri2 und R13, Wasserstoff, C1-6-AI-kyl, CS-y-Cycloalkyl, C2-6~Alkenyl oder Phenyl-Ci-3-alkyl ist und jede der anderen Gruppen, welche gleich oder verschieden sein können, Wasserstoff oder Ci-6-Alkyl bedeutet; für die Herstellung eines Medikaments zum Einsatz bei der Behandlung von durch einen zytotoxischen Wirkstoff oder Bestrahlung ausgelöster Übelkeit und Erbrechen, oder von Reisekrankheit.
2. Verwendung nach Anspruch 1, wobei die Verbindung der Formel(II) die Formel (HA) aufweist:
(HA)
in welcher RiO^- ein Wasserstoff atom oder eine Methyl-,Äthyl-, Propyl-, Prop-2-yl, Prop-2-enyl oder Cyclopentylgruppe ist; R12I ein Wasserstoffatom bedeutet; und entweder RnI eine
Methyl-,Äthyl-, Propyl- oder Prop-2-yl-gruppe ist und R13I ein Wasserstoffatom ist; oder RnI ein Wasserstoffatom darstellt und R13I eine Methyl- oder Äthylgruppe bedeutet.
3. Verwendung nach Anspruch 2, wobei Rio-*- Methyl ist und R12I und R13I jeweils Wasserstoff darstellen.
4. Verwendung nach Anspruch 1, wobei die Verbindung der Formel(II) l,2,3,9-Tetrahydro-9-methyl-3-/"(2-methyl-lH-imidazol-lyl)methyl7-4H-carbazol-4-on oder ein pharmazeutisch verträgliches Salz davon ist.
5. Verwendung nach einem der Ansprüche 1 bis 4, wobei das Medikament zur Verwendung bei der Behandlung von durch einen zytotoxischen Wirkstoff verursachte Übelkeit oder Erbrechen bestimmt ist.
6. Verwendung nach Anspruch 5, wobei der zytotoxische Wirkstoff Cisplatin, Doxorubicin oder Cyclophosphamid ist.
7. Verwendung nach Anspruch 6, wobei der zytotoxische Wirkstoff Doxorubicin oder Cyclophosphamid ist.
8. Verwendung nach Anspruch 6, wobei der zytotoxische Wirkstoff Cisplatin ist und wobei die Verbindung der Formel(II) vor oder nach der Verabreichung von Cisplatin verabreicht wird.
9. Verwendung nach Anspruch 6, wobei der zytotoxische Wirkstoff Cisplatin ist, das intravenös verabreicht wird.
- 10.Verwendung nach einem der Ansprüche 1 bis 4, wobei das Mediv kament zur Verwendung bei der Behandlung von durch Bestrahlung verursachter Übelkeit oder Erbrechen bestimmt ist.
11.Verwendung nach einem der Ansprüche 1 bis 4, wobei das
Medikament zur Verwendung bei der Behandlung von Reisekrankheit bestimmt ist.
DE199090107640T 1985-03-14 1986-03-10 Arzneimittel zur behandlung von erbrechen. Pending DE385517T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB858506642A GB8506642D0 (en) 1985-03-14 1985-03-14 Compounds
GB858509039A GB8509039D0 (en) 1985-04-09 1985-04-09 Treatment
GB858531614A GB8531614D0 (en) 1985-12-23 1985-12-23 Treatment

Publications (1)

Publication Number Publication Date
DE385517T1 true DE385517T1 (de) 1991-07-25

Family

ID=27262620

Family Applications (4)

Application Number Title Priority Date Filing Date
DE199090107640T Pending DE385517T1 (de) 1985-03-14 1986-03-10 Arzneimittel zur behandlung von erbrechen.
DE3689974T Expired - Lifetime DE3689974T2 (de) 1985-03-14 1986-03-10 Arzneimittel zur Behandlung von Emesis.
DE198686301684T Pending DE201165T1 (de) 1985-03-14 1986-03-10 Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
DE90107640T Expired - Lifetime DE3688296T2 (de) 1985-03-14 1986-03-10 Arzneimittel zur behandlung von erbrechen.

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE3689974T Expired - Lifetime DE3689974T2 (de) 1985-03-14 1986-03-10 Arzneimittel zur Behandlung von Emesis.
DE198686301684T Pending DE201165T1 (de) 1985-03-14 1986-03-10 Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
DE90107640T Expired - Lifetime DE3688296T2 (de) 1985-03-14 1986-03-10 Arzneimittel zur behandlung von erbrechen.

Country Status (7)

Country Link
US (3) US4721720A (de)
EP (3) EP0405617A3 (de)
JP (3) JPS61212521A (de)
CY (1) CY1727A (de)
DE (4) DE385517T1 (de)
HK (1) HK77593A (de)
SG (1) SG61693G (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122528A (en) * 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
EP0189002B1 (de) * 1984-12-20 1993-03-03 Sandoz Ag Behandlung von Gastrointestinalkrankheiten durch Anwendung von 5-HT3-Antagonisten
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5204356A (en) * 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
GB8525844D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
DE3777805D1 (de) * 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
GB8628475D0 (en) * 1986-11-28 1987-01-07 Glaxo Group Ltd Medicaments
EP0272052B1 (de) * 1986-12-16 1992-07-08 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Angstlösende N-(1-Azabicyclo[2.2.2)oct-3-yl)benzamide und -thiobenzamide
US5244909A (en) * 1986-12-17 1993-09-14 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
DE3752062T2 (de) * 1986-12-17 1997-09-11 Glaxo Group Ltd Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
DE3788057T2 (de) * 1986-12-17 1994-03-03 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
AU618520B2 (en) * 1986-12-17 1992-01-02 Glaxo Group Limited Medicaments
GB8806990D0 (en) * 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
EP0307077A1 (de) * 1987-07-21 1989-03-15 Merck Frosst Canada Inc. Tetrahydrocarbazole zur Verbesserung der Cyclosporintherapie
CA1307790C (en) * 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
GB8718445D0 (en) * 1987-08-04 1987-09-09 Wyeth John & Brother Ltd Pyridyl-ethers
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
US4863919A (en) * 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
EP0329932B1 (de) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
IT1228288B (it) * 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica
WO1990012569A1 (en) * 1989-04-21 1990-11-01 Sandoz Ag Therapeutic use of 5-ht3 receptor antagonists
AU5650890A (en) * 1989-05-24 1990-12-18 Nippon Shinyaku Co. Ltd. Indole derivatives and medicine
US5223613A (en) * 1990-04-27 1993-06-29 G. D. Searle & Co. Azatetracycle compounds and process of preparing same
US5140023A (en) * 1990-04-27 1992-08-18 G. D. Searle & Co. Azatetracycle compounds
WO1992004347A1 (fr) * 1990-08-31 1992-03-19 Nippon Shinyaku Co., Ltd. Derive d'indole et medicament
US5234921A (en) * 1991-03-07 1993-08-10 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof as pharmaceuticals
US5219850A (en) * 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5516782A (en) * 1991-03-07 1996-05-14 G. D. Searle & Co. New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
US5196547A (en) * 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
EP0528026A1 (de) * 1991-03-07 1993-02-24 G.D. Searle & Co. Meso-azacyclische aromatisch Carbonsäureamide und ester serotonergische Mittel
US5137893A (en) * 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5227377A (en) * 1991-03-07 1993-07-13 G. D. Searle & Co. Meso-azacyclic amides of certain bicyclic carboxylic acids
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
DE4126999A1 (de) * 1991-08-16 1993-02-18 Basf Ag Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots
JP2699794B2 (ja) * 1992-03-12 1998-01-19 三菱化学株式会社 チエノ〔３，２−ｂ〕ピリジン誘導体
DE4238553A1 (de) * 1992-11-14 1994-05-19 Kali Chemie Pharma Gmbh Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel
CN1039623C (zh) * 1993-10-22 1998-09-02 中国人民解放军军事医学科学院毒物药物研究所 一种防治运动病综合征的药物组合物及其制备方法
GB2290963A (en) * 1994-06-28 1996-01-17 Kenneth Francis Prendergast Pharmaceutical uses of ondansetron
JP2002538102A (ja) 1999-03-01 2002-11-12 セプラコア インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282873A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
YU32003A (sh) * 2000-10-30 2006-05-25 Teva Pharmaceutical Industries Ltd. Novi kristalni i solvatni oblici ondansteron hlorovodonika i postupci za njihovo pripremanje
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
KR100434390B1 (ko) * 2001-04-20 2004-06-04 안국약품 주식회사 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
JP2005504059A (ja) * 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
EP1425286B1 (de) * 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituierte 7-aza-[2.2.1]bicycloheptane für die behandlung von krankheiten
IL160884A0 (en) 2001-10-02 2004-08-31 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP2005522456A (ja) 2002-02-15 2005-07-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド
JP2005523288A (ja) * 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
MXPA04008152A (es) * 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
EP1478646A1 (de) * 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclische verbindungen mit activität an alfa7 nikotinischen acetylcholin rezeptoren
PL373191A1 (en) * 2002-04-29 2005-08-22 Teva Gyogyszergyar Reszvenytarsasag Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
JP2005537297A (ja) 2002-08-01 2005-12-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物
BR0315056A (pt) * 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
US20040147510A1 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CN100390172C (zh) * 2004-09-10 2008-05-28 成都欣捷高新技术开发有限公司 一种甲磺酸多拉司琼晶型及其制备方法
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US20090227623A1 (en) * 2007-09-15 2009-09-10 Protia, Llc Deuterium-enriched palosetron
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
CN102887893B (zh) * 2012-10-24 2015-01-14 齐鲁制药有限公司 一种托烷司琼的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB229444A (en) * 1924-01-03 1925-02-26 Frank Samuel Pett Improvements in ships' davits
DE2548968A1 (de) * 1975-11-03 1977-05-12 Thomae Gmbh Dr K Neue amino-benzoesaeureamide
IL59004A0 (en) * 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
FR2493848B2 (fr) * 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
GB2100259B (en) * 1981-06-13 1984-10-31 Merrell Toraude & Co Treatment of migraine with tropyl benzoate derivatives
EP0067615B1 (de) * 1981-06-17 1986-01-08 Beecham Group Plc Alkylthioderivate von Azabicyclobenzamiden, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
AU1508183A (en) * 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
FI74707C (fi) * 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
EP0099194A3 (de) * 1982-07-03 1984-04-11 Beecham Group Plc Benzamide
JPS5967284A (ja) * 1982-07-13 1984-04-16 サンド・アクチエンゲルシヤフト インドリルカルボン酸ピペリジルエステル誘導体
EP0102195A3 (de) * 1982-08-03 1984-04-11 Beecham Group Plc Substituierte Azabicycloalkyl-Derivate mit dopaminantagonistischer Wirkung
JPS5944383A (ja) * 1982-08-03 1984-03-12 ビ−チヤム・グル−プ・ピ−エルシ− 新規な化合物、その製法及びその用途
EP0135545A1 (de) * 1983-02-19 1985-04-03 Beecham Group Plc Azabicycloalkyl-derivate von benzamid und anilid
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
FR2561244B1 (fr) * 1984-01-25 1988-03-04 Glaxo Group Ltd Composes heterocycliques du type tetrahydrocarbazolone, procede pour leur preparation et composition pharmaceutique les comprenant
US4593034A (en) * 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
EP0158265A2 (de) * 1984-04-13 1985-10-16 Beecham Group Plc Benzamid- und Anilid-Derivate
EP0189002B1 (de) * 1984-12-20 1993-03-03 Sandoz Ag Behandlung von Gastrointestinalkrankheiten durch Anwendung von 5-HT3-Antagonisten
EP0191562B1 (de) * 1985-01-23 1991-07-10 Glaxo Group Limited Tetrahydrocarbazolonderivate
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
EP0272052B1 (de) * 1986-12-16 1992-07-08 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Angstlösende N-(1-Azabicyclo[2.2.2)oct-3-yl)benzamide und -thiobenzamide
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product

Also Published As

Publication number Publication date
JPH0720863B2 (ja) 1995-03-08
EP0385517A2 (de) 1990-09-05
HK77593A (en) 1993-08-06
SG61693G (en) 1993-07-09
DE3688296T2 (de) 1993-11-04
JPS61212521A (ja) 1986-09-20
DE3689974D1 (de) 1994-08-25
EP0201165A2 (de) 1986-11-12
DE201165T1 (de) 1989-04-20
JPH05310734A (ja) 1993-11-22
JPH0555484B2 (de) 1993-08-17
EP0201165A3 (en) 1990-08-16
EP0405617A2 (de) 1991-01-02
EP0385517A3 (en) 1990-10-31
EP0201165B1 (de) 1994-07-20
EP0385517B1 (de) 1993-04-14
CY1727A (en) 1994-05-06
DE3688296D1 (de) 1993-05-19
JPH0748372A (ja) 1995-02-21
DE3689974T2 (de) 1994-11-03
US4851407A (en) 1989-07-25
US4721720B1 (de) 1992-06-30
US4721720A (en) 1988-01-26
US4783478A (en) 1988-11-08
EP0405617A3 (en) 1992-11-25

Similar Documents

Publication Publication Date Title
DE385517T1 (de) Arzneimittel zur behandlung von erbrechen.
DE69119495T2 (de) Verfahren zur Behandlung der Parkinson'schen Erkrankung durch Anwendung des ATP-sensitiven Kaliumkanalblockers Chinin
DE69933049T2 (de) Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung
DE69118859T2 (de) Behandlung von Schlafstörungen unter Verwendung bestimmter Antidepressiva, z.B. Nefazodon
Moore et al. Bupivacaine anesthesia—a clinical trial for endodontic therapy
DE280571T1 (de) Matrix-zubereitungen mit verzoegerter freisetzung.
DE60210976T2 (de) Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung
DE2900203A1 (de) Krebshemmendes und krebsmetastasen verhinderndes arzneimittel
DE69304843T2 (de) Methode zur Behandlung von Haarausfall
DE60123528T2 (de) Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit
DE60212710T2 (de) Pharmazeutische zubereitungen enthaltend epothilone und deren verwendung bei der behandlung von karzinoid
DE68916958T2 (de) Topisch angebrachter goldorganokomplex.
DE181050T1 (de) 1-beta-d-ribofuranosyl-1,2,4-triazol-3-carboxamid fuer die verwendung in medizinischer behandlung von menschen.
ATE131065T1 (de) Verwendung von superoxiddismutasen für die herstellung von arzneimitteln zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma als unfallfolge.
DE326326T1 (de) Cysteinderivate.
EP0273199A3 (de) Arzneimittel auf Basis von Derivaten des 3,4-Diphenylpiperidins, die Verwendung der Derivate als Arzneimittel sowie neue 3,4-Diphenylpiperidinderivate und Verfahren zu ihrer Herstellung
DE60019591T2 (de) Behandlung oder hemmung von koronarimplantat vasospasm
DE2327687A1 (de) Antiseptisches mittel
DE2226273C2 (de) Präparate zur Behandlung der Osteoporose
DE2352618A1 (de) Arzneimittel zur behandlung des parkinsonismus
DE2820808A1 (de) Arzneimittel mit einer antanginoesen wirksamkeit
US3354036A (en) Method of producing depression
DE3861866D1 (de) Aspoxicillin enthaltende medizinalzubereitung, ein verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels.
DE2334358A1 (de) Pharmazeutische zubereitungen mit neuartiger wirkung
Billmeier et al. Procarbazine hydrochloride in childhood cancer